project . 2020 - 2021 . Closed

MInfla-Tilc

Generation of therapeutic antibodies targeting type 2 Innate Lymphoid cells in asthma
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 875102 Call for proposal: ERC-2019-PoC
  • Funded under: H2020 | ERC | ERC-POC-LS Funder Contribution: 150,000 EUR
  • Status: Closed
  • Start Date
    01 Jan 2020
    End Date
    31 Dec 2021
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tissue resident cells in the lung, both in human and mouse. Strikingly, the induction of allergic asthma in a mouse model deficient in ILC2s is abolished. In addition, the transfer of ILC2s back in the same mouse recapitulates the pathology. Mechanistically, activated ILC2s are the main producer of type 2 cytokines that sustain the chronicity of asthma by recruiting other inflammatory and pathogenic cells, notably eosinophils, and finally ...
Partners
Description
We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tissue resident cells in the lung, both in human and mouse. Strikingly, the induction of allergic asthma in a mouse model deficient in ILC2s is abolished. In addition, the transfer of ILC2s back in the same mouse recapitulates the pathology. Mechanistically, activated ILC2s are the main producer of type 2 cytokines that sustain the chronicity of asthma by recruiting other inflammatory and pathogenic cells, notably eosinophils, and finally ...
Partners
Any information missing or wrong?Report an Issue